OptimizeRx Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $20.5 million, down 30% year-over-year from $29.2 million in Q2 2025.

Adjusted EBITDA: $4.9 million, compared to $5.8 million in Q2 2025.

Net Loss: $700,000 or $0.04 per share, compared to net income of $1.5 million or $0.08 per share in the same period last year.

Non-GAAP Net Income: $3.1 million or $0.16 per diluted share, down from $3.7 million or $0.19 per diluted share in Q2 2025.

Cash Balance: $24.1 million at the end of Q2 2026.

Debt: Reduced to $19.7 million, with an additional $3 million paid off post-quarter.

Average Revenue per Top 20 Pharmaceutical Manufacturer: $2.7 million.

Net Revenue Retention Rate: 90%, down from previous levels, primarily due to a few large accounts optimizing spend.

2Strategic Updates and Business Highlights

Continued investment in platform capabilities, including the launch of new products such as:

DeepIntent Integration: First healthcare demand-side platform integrated with OptimizeRx's EHR network.

Natural Language Audience Builder (NLAB): AI-powered tool for creating customized healthcare provider audiences.

CopayQ: A solution providing real-time copay activation to improve patient access.

Transitioning towards recurring subscription revenue, with AI-enabled software offerings growing 25% year-over-year.

Focus on expanding among mid-sized and emerging life science companies, seen as a significant growth opportunity.

Leadership transition planned with Edward Stelmakh stepping down as CFO at the end of 2026, succeeded by Andrew D'Silva.

3Forward Guidance and Outlook

Full-year 2026 revenue guidance reaffirmed at $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million.

Anticipation of stronger revenue in the second half of the year, particularly Q4, which is expected to account for 35% to 40% of total annual revenue.

4Bad News, Challenges, or Points of Concern

Revenue decline attributed to a limited number of large customers and lower-margin managed services.

Continued cautious spending behavior from pharmaceutical clients due to macroeconomic factors and regulatory pressures.

Net revenue retention rate decline indicates potential challenges in maintaining existing customer revenue.

Uncertainty regarding the recovery of a significant client that has not generated revenue in the current quarter.

5Notable Q&A Insights

Management does not expect the previously mentioned large client to contribute in the second half but is seeing positive engagement and discussions.

The integration with DeepIntent is live, and management is optimistic about the potential growth from this partnership, noting that 60% of buys in the space are now through programmatic channels.

The company is cautiously optimistic about potential regulatory changes that could shift spending from traditional advertising to digital and point-of-care engagements.

Management emphasized that while macroeconomic concerns persist, they are seeing normalization in spending patterns among pharmaceutical clients.

Plans for capital allocation focus primarily on debt reduction, with potential for stock buybacks if stock prices remain low. Overall, while OptimizeRx faces challenges in revenue generation and client retention, strategic initiatives and a focus on innovation position the company for potential growth in the coming quarters.